Clinical Trials Logo

Systemic Lupus Erythematosus clinical trials

View clinical trials related to Systemic Lupus Erythematosus.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 7

NCT ID: NCT03396393 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

Exploratory Study of DHA in Systemic Lupus Erythematosus Patients

Start date: March 2018
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to assess the efficacy of DHA in patients with SLE.

NCT ID: NCT03219801 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Systemic Lupus Erythematosus

Start date: August 1, 2017
Phase: Early Phase 1
Study type: Interventional

This study is to evaluate the safety and efficacy of human umbilical cord derived mesenchymal stem cells transplantation in systemic lupus erythematosus.

NCT ID: NCT03178721 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

Regulatory BCells in Systemic Lupus Erythematosus

Start date: June 25, 2017
Phase: N/A
Study type: Observational [Patient Registry]

Systemic lupus erythematosus , the archetypal multisystem autoimmune disease, presents many diagnostic and management challenges. One such challenge is the excess cardiovascular disease observed in patients with Systemic lupus erythematosus . Coronary heart disease and other manifestations of atherosclerosis continue to be a major cause of death in patients with Systemic lupus erythematosus.Regulatory B-cells have been identified as a negative regulator of the immune system that inhibit pathological immune response by suppressing both uncontrolled protective immune response and damaging autoimmune responses

NCT ID: NCT03165682 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

Fatigue, Depression, and Cortical Excitability in Systemic Lupus

Start date: December 1, 2018
Phase:
Study type: Observational

Systemic lupus erythematosus is a chronic inflammatory autoimmune disease with an unknown cause and many challenges. Whilst corticosteroids and effective immunosuppressive therapy have transformed the management of patients with active systemic lupus erythematosus, one of the major causes of morbidity in Systemic lupus erythematosus patients is chronic, debilitating fatigue. Despite frequent occurrence of fatigue in Systemic Lupus Erythematosus, to the best of our knowledge, no studies have been directly performed to examine fatigue-related changes in cortical motor function in Systemic lupus erythematosus. In this study, we hypothesized that Systemic lupus erythematosus patients with fatigue and depression versus Systemic lupus erythematosus patients without fatigue and depression would present an alteration of motor cortex excitability.

NCT ID: NCT01460680 Not yet recruiting - Fibromyalgia Clinical Trials

Membrane Polyunsaturated Fatty Acid Content in Fibromyalgia and Systemic Lupus Erythematosus (SLE)

Start date: November 2011
Phase: N/A
Study type: Observational

Polyunsaturated omega-3 fatty acids (ω3 PUFAs) are essential nutrients. Studies indicate that the incidence of Major Depression (MD) is inversely related to the consumption of fish (which are rich in ω3-PUFAs) and to the concentration of ω3 PUFAs in the plasma or Red Blood Cell (RBC) membranes. In several studies, the ω6 to ω3 ratio was elevated (ω6 PUFAs are pro-inflammatory, compared to ω3). ω3 PUFAs are also inversely associated with anxiety and neuroticism but apparently not with somatization. Supplementation of fish oil alleviates joint pain in patients with auto-immune disease. Inhibition of pro-inflammatory cytokines (which induce both pain and depression-like symptoms) by ω3 PUFAs may underlie the benefit conferred by fish oil consumption . RBC ω3 PUFA content is lower in patients with Systemic Lupus Erythematosus and chronic fatigue syndrome, compared to healthy controls. The ω3 PUFA status of fibromyalgia patients has not been assessed. Magnesium is an essential nutrient and plays a regulatory role in neural transmission. It is not known whether magnesium concentration is associated with pain in humans. The objectives of the current study are to 1) compare the mean RBC omega-3 content in female fibromyalgia patients compared to that of healthy controls and female SLE patients, and to 2) assess the correlation between RBC omega-3 content and between the severity of physical (e.g. pain) and mental (e.g. depression) in fibromyalgia and Systemic Lupus Erythematosus (SLE).